Skip to main content

Table 2 BladMetrix sensitivity across tumor stages and grades

From: BladMetrix: a novel urine DNA methylation test with high accuracy for detection of bladder cancer in hematuria patients

  BlCa cases, discovery series (n = 26) BlCa cases, hematuria series (n = 93)
Conclusive patients 88.5% (23/26) 95.7% (89/93)
Stages
Ta 100% (11/11) 85% (33/39)
T1 97% (30/31)
T2 100% (3/3) 100% (9/9)
T3 100% (4/4) 100% (1/1)
T4 100% (2/2)
CIS 80% (4/5) 100% (7/7)
Grade
Low-grade 100% (7/7) 85% (23/27)*
High-grade 94% (15/16) 95% (57/60)*
  1. The sensitivity of BladMetrix to detect bladder tumors of different stages and grades is shown for the discovery series and the hematuria series
  2. BlCa Bladder cancer
  3. *Grade is missing for two of the included patients